Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.

Inclusion Criteria: * Patients with long-term intestinal failure who will receive PS at least 2 times /week over a subcutaneously tunneled single-lumen CVC (Hickman/Broviac) for at least one year. * Estimated life expectancy ≥1 year * Male or female patient aged 18 - 80 years * Patient is fully able to understand the nature of the proposed intervention and gives written informed consent before entering the trial. Exclusion Criteria: Patients who: * can not be expected to comply with the trial plan (e.g. substance abuse, mental condition) * has significant cardiovascular disease such as unstable angina, recent acute myocardial infarction or recent cerebral vascular accident (within 6 weeks); a cardiac rhythm which in the investigators judgment may result in significant hemodynamic effects * has a known hypersensitivity/allergy to TauroLockTMHep 100 or heparin and/or their excipients. * is pregnant, lactating, or nursing * has abnormal blood coagulation due to primary disease or due to treatment with anticoagulants (warfarin/phenprocoumon, unfractionated heparin, low- molecular heparin), with the clinical blood tests INR and APTT, outside the intervals given below, at the time of inclusion. Patients with unfractionated Heparin 100 IE/ml used as a catheter lock, do not need to have APTT tested before enrollment. Patients treated with Low-Molecular Heparin, needs control of INR, thrombocytes and plasma-antifactor Xa, and If the patient has increased bleeding risk judge by disease and clinical blood tests, the patient can´t be included in the trial. INR 0.9-3.0 (warfarin/ phenprocoumon) APTT needs to be in the range 25-100 seconds (Unfractionated Heparin treatment) Plasma-antifactor Xa( outside recommended intervals (pro.medicin.dk), which are dependent on administration form and number of daily administrations ). Thrombocytes 100- 600 x109/L * Patients with a new catheter-related thrombosis in the last 3 months prior to inclusion. * has received an investigational drug within 30 days of trial entry * has received a TauroLockTMHep 100 solution previously * has an antibiotic coated, silver impregnated or antimicrobial cuff catheter * has compromised skin integrity, including any infection at the insertion site